Immunome (NASDAQ:IMNM – Get Free Report) and Oculis (NASDAQ:OCS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.
Insider and Institutional Ownership
44.6% of Immunome shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 8.6% of Immunome shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Immunome and Oculis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immunome | -3,014.59% | -48.63% | -41.62% |
| Oculis | -8,043.28% | -71.31% | -56.85% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immunome | 0 | 0 | 7 | 0 | 3.00 |
| Oculis | 0 | 0 | 5 | 0 | 3.00 |
Immunome presently has a consensus target price of $28.83, indicating a potential upside of 170.48%. Oculis has a consensus target price of $28.80, indicating a potential upside of 54.01%. Given Immunome’s higher probable upside, analysts clearly believe Immunome is more favorable than Oculis.
Earnings & Valuation
This table compares Immunome and Oculis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immunome | $10.13 million | 65.69 | -$106.81 million | ($8.11) | -1.31 |
| Oculis | $980,000.00 | 772.88 | -$98.92 million | ($1.93) | -9.69 |
Oculis has lower revenue, but higher earnings than Immunome. Oculis is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Immunome has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500. Comparatively, Oculis has a beta of -0.33, meaning that its stock price is 133% less volatile than the S&P 500.
Summary
Immunome beats Oculis on 10 of the 13 factors compared between the two stocks.
About Immunome
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
About Oculis
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.
Receive News & Ratings for Immunome Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunome and related companies with MarketBeat.com's FREE daily email newsletter.
